Protalix Biotherapeutics, Inc. (PLX) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024, for Protalix Biotherapeutics, Inc., a commercial-stage biopharmaceutical company. The company utilizes its proprietary ProCellEx plant cell-based protein expression system to develop and manufacture recombinant therapeutic proteins. Protalix operates as a single segment with its primary manufacturing and operations located in Carmiel, Israel. The company holds two approved commercial products: Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Total Revenue | $53.4 million | $65.5 million |
| Net Income | $2.9 million | $8.3 million |
| Operating Income | $3.9 million | $10.5 million |
| Cost of Goods Sold | $24.3 million | $23.0 million |
| Research & Development Expenses | $13.0 million | $17.1 million |
| Cash and Cash Equivalents | $19.8 million | $23.6 million |
| Short-term Bank Deposits | $15.1 million | $20.9 million |
| Total Liquidity (Cash + Deposits) | $34.8 million | $44.5 million |
| Debt (Convertible Notes) | $0 | $20.3 million |
Note: Revenue decreased primarily due to the absence of a $20.0 million regulatory milestone payment from Chiesi recognized in 2023. Product sales revenue increased by 31% year-over-year.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue declined 18% to $53.4 million. While revenue from selling goods increased to $53.0 million (up 31%), revenue from license and R&D services dropped to $0.4 million (down 98%) following the completion of major regulatory milestones in 2023.
- Debt Repayment: In September 2024, the company repaid in full all outstanding principal and interest ($21.2 million) on its 2024 Convertible Notes using available cash and short-term deposits. Consequently, the company ended the year debt-free.
- Profitability: Net income decreased to $2.9 million from $8.3 million in 2023, driven by the loss of the milestone revenue and increased tax provisions related to GILTI income and Section 174 amortization of R&D expenses.
- Expense Reduction: R&D expenses decreased by 24% ($4.1 million) due to the completion of the Fabry clinical program and regulatory review processes for Elfabrio.
Guidance, Outlook, and Management Commentary
- Commercialization: Elfabrio sales to Chiesi reached $29.3 million in 2024. In December 2024, the EMA validated a variation submission to label a less frequent dosing regimen (2 mg/kg every four weeks) for Elfabrio, potentially improving patient convenience.
- Pipeline Progress: The Phase I First-in-Human trial for PRX-115 (PEGylated uricase for uncontrolled gout) was completed with positive results. The company expects to commence a Phase II clinical trial for PRX-115 in the second half of 2025.
- Liquidity Outlook: Management believes current cash and short-term deposits ($34.8 million) are sufficient to satisfy capital needs for at least 12 months from the filing date. The company completed its At-The-Market (ATM) equity offering program in early 2025.
- Risks and Contingencies:
- Geopolitical Risk: Operations in Israel face risks from ongoing regional conflicts (Hamas/Hezbollah). While the company states operations have not been adversely affected to date, it has stored drug substance in multiple locations to mitigate risk.
- Brazil Agreement: Fiocruz (Brazilian Ministry of Health) has not met purchase commitments for Elelyso (marketed as BioManguinhos alfataliglicerase). The company retains the right to terminate the agreement but continues to supply the product.
- Regulatory: Elfabrio carries a boxed warning for hypersensitivity reactions/anaphylaxis.
Key Facts for Investor Verification
- Revenue Sustainability: Verify the trajectory of Elfabrio sales to Chiesi to ensure they can offset the loss of one-time milestone revenues and sustain operations without further equity dilution.
- Debt-Free Status: Confirm the company remains debt-free following the September 2024 repayment of the 2024 Notes.
- PRX-115 Timeline: Monitor the commencement of the Phase II trial for PRX-115 in late 2025 as a key value driver for the pipeline.
- Brazilian Operations: Assess the stability of the Brazil Agreement with Fiocruz and the potential impact of continued non-compliance on revenue from the Brazilian market.
- Geopolitical Exposure: Review updates on the impact of the Israel-Hamas/Hezbollah conflict on manufacturing continuity and supply chain logistics.